文献速递乳腺乳腺X线

乳腺X线筛查中的假阳性召回率与假阳性活检率:TOSYMA试验亚分析

False-Positive Recall and False-Positive Biopsy Rates in Mammography Screening: A TOSYMA Trial Subanalysis.
PubMed 文献 · Radiology · 2025-01-01

基于TOSYMA随机试验的探索性亚分析显示,在50-70岁女性中,与数字乳腺X线摄影(DM)相比,数字乳腺断层摄影(DBT)联合合成乳腺X线摄影(SM)的真阳性召回率更高(8.4 vs 6.2/1000),假阳性召回率更低(40.2 vs 43.7/1000),尤其在首轮筛查中差异更明显;DBT+SM的假阳性活检率略高(差异1.8/1000),但被更多检出的乳腺癌所补偿。

要点

  • DBT+SM组假阳性召回率40.2/1000,低于DM组的43.7/1000,首轮筛查中差异更明显(94.0 vs 109.6/1000)。
  • DBT+SM组真阳性召回率8.4/1000,高于DM组的6.2/1000,召回阳性预测值17.2% vs 12.3%。
  • DBT+SM组假阳性活检率较DM高1.8/1000(CI: 0.0, 3.6),但活检阳性预测值差异无统计学意义。

核心结论

  • 这项大型随机TOSYMA试验的探索性分析表明,DBT+SM的假阳性召回率低于DM,尤其在首轮筛查参与者中;DBT+SM轻度升高的假阳性活检被更多检出的乳腺癌所补偿。

研究设计与样本

  • TOSYMA随机试验(NCT03377036)的探索性亚分析,2018年7月至2020年12月纳入50-70岁女性(平均年龄57.7岁±5.6),1:1分配至DBT+SM组或DM组,DM组49762例、DBT+SM组49715例,对假阳性发现者随访24个月。

诊断标准与关键数值

  • 召回率:DBT+SM组48.6/1000(2416/49715) vs DM组49.9/1000(2483/49762);真阳性召回率:DBT+SM组8.4/1000(416/49715) vs DM组6.2/1000(306/49762),差异2.2/1000(CI: 0.4, 4.0);假阳性召回率:DBT+SM组40.2/1000(2000/49715) vs DM组43.7/1000(2177/49762),差异-3.5/1000(CI: -7.8, 0.7);首轮筛查假阳性召回率:DBT+SM组94.0/1000 vs DM组109.6/1000,差异-15.6/1000(CI: -31.0, -0.2);召回阳性预测值:DBT+SM组17.2%(416/2416) vs DM组12.3%(306/2483),差异4.9%(CI: 1.5, 8.3);假阳性活检率:DBT+SM组7.8/1000(388/49715),较DM高1.8/1000(CI: 0.0, 3.6);活检阳性预测值:51.7%(416/804),差异1.1%(CI: -7.9, 10.2)。

临床应用与阅片要点

  • 作者认为DBT+SM的假阳性召回率低于DM,尤其在首轮筛查中,且轻度升高的假阳性活检被更多检出的乳腺癌所补偿;该分析为严格探索性。

局限性

  • 原文明确说明该分析为严格探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background False-positive results may negatively affect participants and diminish the efficiency of mammography screening programs. Purpose To assess whether the higher breast cancer detection rate with digital breast tomosynthesis (DBT) plus synthesized mammography (SM) compared with digital mammography (DM) in the randomized TOmosynthesis plus SYnthesized MAmmography (TOSYMA) trial comes with higher false-positive rates. Materials and Methods The TOSYMA trial was conducted from July 2018 to December 2020 in women aged 50-70 years (mean age, 57.7 years ± 5.6 [SD]), with 1:1 allocation to the DBT plus SM or DM study arm (NCT03377036). True- and false-positive recall rates, false-positive biopsy rates, and positive predictive values of recalls and biopsies performed were compared per arm. Women with false-positive findings were followed up for 24 months. The analyses were strictly exploratory. Results There were 49 762 women in the DM arm and 49 715 in the DBT plus SM arm. The recall rate was 48.6 per 1000 women screened (2416 of 49 715) with DBT plus SM and 49.9 per 1000 women screened (2483 of 49 762) with DM. The true-positive recall rate of DBT plus SM (8.4 per 1000 women screened; 416 of 49 715) was higher than that of DM (6.2 per 1000 women screened; 306 of 49 762), a difference of 2.2 per 1000 women screened (CI: 0.4, 4.0). The false-positive recall rate was lower with DBT plus SM (40.2 per 1000 women screened; 2000 of 49 715) than with DM (43.7 per 1000 women screened [2177 of 49 762]; difference: -3.5 per 1000 women screened [CI: -7.8, 0.7]), particularly in the first screening round (DBT plus SM: 94.0 per 1000 women; DM: 109.6 per 1000 women screened; difference, -15.6 per 1000 women screened [CI: -31.0, -0.2]). The positive predictive value of recall was higher with DBT plus SM (17.2%; 416 of 2416 women recalled) than with DM (12.3% [306 of 2483 women recalled]; difference, 4.9% [CI: 1.5, 8.3]). The false-positive biopsy rate (7.8 per 1000 women screened; 388 of 49 715) was higher with DBT plus SM (1.8 per 1000 women screened; CI: 0.0, 3.6), and the positive predictive value of biopsies performed was 51.7% (416 of 804 women with biopsies performed; difference, 1.1%; CI: -7.9, 10.2). Interval cancers after false-positive recalls were rare (five with DBT plus SM and two with DM). Conclusion This exploratory analysis of the large randomized TOSYMA trial indicates that DBT plus SM showed lower false-positive recall rates than DM, especially in first-round screening participants. Mildly raised false-positive biopsies of DBT plus SM were compensated by more detected breast cancers. ClinicalTrial.gov identifier: NCT03377036 © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Mesurolle in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Weigel S, Hense HW, Weyer-Elberich V, et al. False-Positive Recall and False-Positive Biopsy Rates in Mammography Screening: A TOSYMA Trial Subanalysis. Radiology. 2025. PMID: 40956160. doi:10.1148/radiol.251014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。